| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5094
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2001-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75488c3b505a3bfa09713e44e75ad356
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd51a8abf48dc201731ce1d1cf0a8000
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e308161d9103bf72bfc0b94ed43470df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a562353cf61d19ccd0f6a273ac53850d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f38829952e839134f3f74d37d758a8d |
| publicationDate |
2004-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2004023312-A1 |
| titleOfInvention |
Method for diagnosing huntingtons disease and means of treating it |
| abstract |
The invention is based on the identification of abnormal behaviour of the adenosine A 2A receptor, both as regards the bond to specific ligands and its coupling to the adenylate cyclase system characteristic of cells genetically predisposed to develop Huntington's Disease and of circulating cells in patients affected by this disease. The present invention uses this abnormal behaviour as a diagnostic marker for early detection of the onset and/or progression of this disease, and as a pharmacological target to inhibit to delay progression of the pathology. The invention consists in an in-vitro method for diagnosing Huntington's disease based on assessment of the increase in the number of A 2A receptors for adenosine and/or of the abnormal activity of adenylate cyclase, and in the use of drugs that inhibit this activity, for the prevention and/or treatment of this disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004049484-A1 |
| priorityDate |
2000-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |